US Stock Insider Trading | Veracyte disclosed 7 insider transactions on March 4

K-LinePoet · 2026-03-28T18:58:48+00:00

Veracyte disclosed multiple insider transactions on March 2, 2026, including stock sales by Director Stapley Marc and several executives, with a significant total transaction amount. The company focuses on molecular cytology diagnostics aimed at improving diagnostic accuracy and reducing unnecessary medical interventions.

K-LinePoet

2026-03-28 18:58:48

Abstract generation in progress

On March 4, 2026, Veracyte (VCYT) disclosed 7 transactions involving company insiders. Director Stapley Marc sold 19,500 shares on March 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 4, 2026	Executive	Wygant Jonathan	March 2, 2026	Sell	3006	36.01	108,200
March 4, 2026	Executive	Febbo Phillip G.	March 2, 2026	Sell	6035	36.01	217,300
March 4, 2026	Executive	Febbo Phillip G.	March 2, 2026	Sell	13,400	36.16	485,400
March 4, 2026	Executive	McGuire Annie	March 2, 2026	Sell	6902	36.01	248,500
March 4, 2026	Executive	Chambers Rebecca	March 2, 2026	Sell	7234	36.01	260,500
March 4, 2026	Executive	Leite John	March 2, 2026	Sell	7517	36.01	270,700
March 4, 2026	Director	Stapley Marc	March 2, 2026	Sell	19,500	36.01	700,600
March 2, 2026	Director	Stapley Marc	February 26, 2026	Sell	35,800	38.75	1,388,500
March 2, 2026	Executive	McGuire Annie	February 26, 2026	Sell	10,900	38.75	421,100
March 2, 2026	Executive	Chambers Rebecca	February 26, 2026	Sell	12,000	38.75	466,900

[Company Information]

Veracyte, Inc. was incorporated in Delaware on August 15, 2006, as a subsidiary of Calderome Holdings.

Until early 2008, Calderome operated as a startup incubator. On March 4, 2008, the company changed its name to Veracyte, Inc. Veracyte is a pioneering diagnostics company in the field of molecular cytology, focused on improving patient outcomes and reducing healthcare costs. The company specializes in achieving accurate diagnoses for diseases that often require invasive procedures—many healthy patients undergo costly interventions that ultimately prove unnecessary. The company derives clinically actionable genomic information from samples collected in outpatient cytology, enhancing diagnostic accuracy in patient care at an earlier stage. The company’s first commercial solution—Afirma Thyroid FNA Analysis—features a gene expression classifier (GEC) at its core. The GEC helps physicians reduce unnecessary surgeries by preoperatively determining whether previously classified indeterminate thyroid nodules can be reclassified as benign, using a proprietary panel of 142 gene markers. The company is headquartered in South San Francisco, California, and Austin, Texas, and operates in one segment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.